Lynparza™ (olaparib) granted Breakthrough Therapy designation by US FDA for …

Lynparza™ (olaparib) granted Breakthrough Therapy designation by US FDA for …

The Breakthrough Therapy designation for Lynparza is encouraging news for patients, and their families, as there are currently very limited treatment options for metastatic Castration Resistant Prostate Cancer. We will work closely with the FDA to

(Visited 3 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.